Other Events ·
Inhibikase Therapeutics, Inc. dismissed CohnReznick LLP as its independent registered public accounting firm effective…
IKTInhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. dismissed CohnReznick LLP as its independent registered public accounting firm effective August 21, 2026, and appointed Deloitte & Touche LLP to replace them for the fiscal year ending December 31, 2026. The company confirmed that audit reports from CohnReznick for fiscal years ended December 31, 2025, and 2024 contained no adverse opinions or qualifications. There were no disagreements between the company and CohnReznick regarding accounting principles, financial statement disclosures, or auditing scope. A material weakness in internal control over financial reporting was previously disclosed for the quarter ended June 30, 2024, but had been remediated by September 30, 2024. The filing includes a letter from CohnReznick dated August 26, 2026. Inhibikase Therapeutics operates in the biotechnology industry, focusing on developing therapies for rare genetic diseases.